Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Prepares To Test Drive Biosimilar Pathway In The U.S.

Executive Summary

Merck is gearing up to test the new regulatory pathway for biosimilar drugs in the U.S. and is hoping to be the first drug maker to move a biologic through the abbreviated process, Merck BioVentures President Michael Kamarck said in an interview June 28
Advertisement

Related Content

"The Pink Sheet" – Most Notable Stories Of 2010
Biosimilars May Drift, But What Should FDA Do About It?
FOBs: Industry Begins To Plot Course Along Pathway As It Awaits FDA Policy
FOBs: Industry Begins To Plot Course Along Pathway As It Awaits FDA Policy
Sandoz Will Steer Clear Of U.S. Biosimilars Pathway, Use Other Applications
On The Cusp Of Biosimilars: Reform Ushers In Next Generic Drug Era
On The Cusp Of Biosimilars: Reform Ushers In Next Generic Drug Era
Merck Buys Contract Manufacturing Org Avecia To Advance Biologics Strategy
Teva, Eyeing Follow-Ons For Most Biologics, Starts With Amgen's Neupogen
Merck’s Ambitious Plans For Follow-On Biologics

Topics

Advertisement
UsernamePublicRestriction

Register

PS052397

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel